Research Tracker›Biomarker Atlas›Marker Pages›Vaccine mRNA (hybrid 3'UTR motifs)

Vaccine mRNA (hybrid 3'UTR motifs): biomarker evidence

Vaccine mRNA (hybrid 3'UTR motifs) appears in 1 entry of the OSMF biomarker atlas, covering PACVS. Across those entries it is mixed in 1. It is currently reported in a single condition in this atlas; cross-condition comparison will be added as the dataset grows. Each row below links to a page with the comparison group, associated symptoms, test details and primary citation.

PACVS

Where Vaccine mRNA (hybrid 3'UTR motifs) is reported

Also listed as: mtRNR1 / AES sequences

ConditionDirectionCompared againstAssociated symptomsSource
PACVS↕ inconsistentViral RNADistinguishes vaccine from viral RNACamperi et al. 2025

Frequently asked questions

In which conditions is Vaccine mRNA (hybrid 3'UTR motifs) altered?

In the OSMF atlas Vaccine mRNA (hybrid 3'UTR motifs) is reported in PACVS. It is mixed in 1 across 1 entries.

Is there a standard clinical test for Vaccine mRNA (hybrid 3'UTR motifs)?

The atlas entries for Vaccine mRNA (hybrid 3'UTR motifs) do not carry a LOINC code, which usually means the marker was measured with research assays or study-specific methods rather than a routine clinical panel.

Is one abnormal Vaccine mRNA (hybrid 3'UTR motifs) result diagnostic?

No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.

Cite this page

Open Source Medicine Foundation. (2026). Vaccine mRNA (hybrid 3'UTR motifs) across conditions: biomarker evidence. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/markers/vaccine-mrna-hybrid-3utr-motifs.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-30 · Browse: Biomarker Index · All marker pages · Biomarker Atlas

Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.